Anaptysbio, Inc (ANAB) Stock Price & Analysis
Anaptysbio, Inc (ANAB) fell 1.38% to USD 54.15 as of July 25, 2026 at 04:19 UTC, according to Nexqual real-time market data.
ANAB last closed at USD 54.91; the session ranged USD 53.26–55.16 on volume of 467,729 shares. Market capitalization is $1.60B, with a 52-week range of USD 11.4–72.36 (NMS). Source: Nexqual, July 25, 2026 at 04:19 UTC.
Key Statistics (as of July 25, 2026 at 04:19 UTC)
| Price | USD 54.15 |
|---|---|
| Change | ▼ 1.38% (down) |
| Previous Close | USD 54.91 |
| Open | USD 55.16 |
| Day Range | USD 53.26 – 55.16 |
| 52-Week Range | USD 11.4 – 72.36 |
| Volume | 467,729 shares |
| Market Cap | $1.60B |
| Exchange | NMS |
Technical Analysis (ANAB)
Nexqual's technical model rates ANAB "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.89 (neutral) |
| vs SMA50 | Below (USD 58.53) |
| MACD | -1.65 (negative) |
Analyst Ratings (ANAB)
Wall Street analysts rate ANAB "Strong Buy" based on 11 analysts, with a mean price target of USD 87.09 (range USD 70–140), per Nexqual as of July 25, 2026 at 04:19 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 87.09 |
| High Target | USD 140 |
| Low Target | USD 70 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (ANAB)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.14 |
| Revenue Estimate | $17.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 1.58 vs est 0.93 ▲ beat |
| 2025-09-30 | USD 0.52 vs est -1.25 ▲ beat |
| 2025-06-30 | USD -1.34 vs est -1.58 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financials & Fundamentals (ANAB)
| Total Revenue | $232.39M |
|---|---|
| Revenue Growth (YoY) | -8.00% |
| Gross Margin | +44.58% |
| Operating Margin | -135.53% |
| Profit Margin | -11.53% |
| ROE | -114.55% |
| Debt / Equity | 2,175.85 |
| Current Ratio | 7.58 |
| Total Cash | $286.46M |
| Total Debt | $277.36M |
| Free Cash Flow | $8.32M |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financial Health Score (ANAB)
Nexqual rates Anaptysbio, Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:19 UTC.
| Growth | Strong — Revenue +157% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $286M cash vs $277M debt, net cash position |
| Cash Flow | Mixed — FCF $8M, slim 3.5% margin |
| Efficiency | Critical — ROE -115%, ROA 6.8% |
Ownership (ANAB)
| Insider Ownership | +5.68% |
|---|---|
| Institutional Ownership | +100.67% |
| Shares Outstanding | 29.61M |
| Float | 19.79M |
| Short % of Float | +38.70% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Leadership (ANAB)
Anaptysbio, Inc is led by Daniel R. Faga (age 45), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:19 UTC.
| President, CEO & Director | Daniel R. Faga (age 45) |
|---|---|
| Chief Financial Officer | Christopher M. Murphy (age 41) |
| Senior Vice President of Human Resources | Beth Mueller |
| Senior Vice President of Research | Martin Dahl |
| Senior Vice President of Corporate Affairs | Monique Da Silva |
Major Backers & Investors (ANAB)
Notable institutional backers of Anaptysbio, Inc include EcoR1 Capital, LLC, Tang Capital Management, LLC, Morgan Stanley, according to Nexqual as of July 25, 2026 at 04:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| EcoR1 Capital, LLC | 26.61% |
| Tang Capital Management, LLC | 4.49% |
| Morgan Stanley | 3.36% |
| Affinity Asset Advisors, Llc | 3.17% |
| Sanofi | 2.78% |
| Palo Alto Investors Lp | 2.16% |
| 683 Capital Management LLC | 2.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.82% |
| Vanguard Group | 6.28% |
| State Street | 6% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
From Anaptysbio, Inc's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
- It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
- It has collaborations agreement with GSK and Vanda.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XNCR | Xencor, Inc. | USD 19.44 | ▼ 0.36% |
| KURA | Kura Oncology, Inc. | USD 10.39 | ▼ 1.42% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 102.1 | ▼ 1.8% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| SNDX | Syndax Pharmaceuticals, Inc. | USD 20.81 | ▼ 5.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:19 UTC. This page is informational and not investment advice.